NCT06654622Completed
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 175 (actual)
- First submitted
- 21 Oct 2024
- Start date
- 1 Apr 2023
- Primary completion date
- 18 Jan 2026
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Colorectal cancer
- NCT number
- NCT06654622
What you commit to
- Study type: Observational
- Participants enrolled: 175
- From 1 Apr 2023 to the primary completion date, 18 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with stage IV cancer or those receiving neoadjuvant therapy.
- Patients with non-curative resection or requiring urgent surgery.
Other
- Patients with a follow-up period of fewer than 3 years.
- Patients with severe comorbidities or who are unable to participate in follow-up assessments.
Who the study is looking for
- Patients with pathologically confirmed stage II or III colorectal cancer.
- Patients who have undergone curative-intent surgery.
- Patients with no evidence of distant metastasis (stage IV).
- Patients aged 18 years or older.
- Patients who provided written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.